| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fc2a22a9271507062ad7e07974d3c58 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-141
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10371
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10332
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10032
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12R2001-91 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 |
| filingDate |
2019-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e9e35df6c80ef11260c256acfa2ae79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76f7f19c27bfe1c627277d6d460066f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8f327facabccf2b4974d7dc86d560d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f66e125194089e61312d45a7953016f7 |
| publicationDate |
2019-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019199859-A1 |
| titleOfInvention |
Oncolytic adenovirus compositions with enhanced replication properties |
| abstract |
Tumor-selective recombinant adenoviruses that possess deletions or modifications in the E3 region are described. Recombinant adenoviruses that express adenovirus death protein (ADP) but have a deletion of at least three of the remaining six E3 genes exhibit enhanced virus replication. The recombinant adenoviruses further include additional modifications to allow selective replication in tumor cells and to detarget viruses from the liver. Use of the recombinant adenoviruses for cancer treatment is described. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021207136-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11077156-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11401529-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022010946-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11130968-B2 |
| priorityDate |
2018-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |